Found: 46
Select item for more details and to access through your institution.
BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer.
- Published in:
- Current Oncology Reports, 2019, v. 21, n. 2, p. 1, doi. 10.1007/s11912-019-0762-x
- By:
- Publication type:
- Article
Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
- Published in:
- International Journal of Molecular Sciences, 2020, v. 21, n. 3, p. 1060, doi. 10.3390/ijms21031060
- By:
- Publication type:
- Article
Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma.
- Published in:
- 2017
- By:
- Publication type:
- journal article
The ATR inhibitor elimusertib exhibits anti‐lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 1, p. 191, doi. 10.1111/bjh.19218
- By:
- Publication type:
- Article
In vitro anti‐lymphoma activity of the first‐in‐class pan‐NOTCH transcription inhibitor CB‐103.
- Published in:
- British Journal of Haematology, 2023, v. 200, n. 5, p. 669, doi. 10.1111/bjh.18576
- By:
- Publication type:
- Article
Pembrolizumab in relapsed or refractory Richter syndrome.
- Published in:
- British Journal of Haematology, 2020, v. 190, n. 2, p. e117, doi. 10.1111/bjh.16762
- By:
- Publication type:
- Article
Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP‐319 in pre‐clinical models of aggressive lymphomas.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 5, p. 595, doi. 10.1111/bjh.16118
- By:
- Publication type:
- Article
Late relapse in patients with diffuse large B‐cell lymphoma: impact of rituximab on their incidence and outcome.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 4, p. 478, doi. 10.1111/bjh.16106
- By:
- Publication type:
- Article
In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas.
- Published in:
- British Journal of Haematology, 2019, v. 186, n. 1, p. 149, doi. 10.1111/bjh.15727
- By:
- Publication type:
- Article
Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma.
- Published in:
- British Journal of Haematology, 2019, v. 184, n. 6, p. 1022, doi. 10.1111/bjh.15212
- By:
- Publication type:
- Article
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.
- Published in:
- British Journal of Haematology, 2017, v. 178, n. 6, p. 936, doi. 10.1111/bjh.14803
- By:
- Publication type:
- Article
The novel atypical retinoid ST5589 down-regulates Aurora Kinase A and has anti-tumour activity in lymphoma pre-clinical models.
- Published in:
- British Journal of Haematology, 2015, v. 171, n. 3, p. 378, doi. 10.1111/bjh.13595
- By:
- Publication type:
- Article
Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group.
- Published in:
- British Journal of Haematology, 2014, v. 166, n. 1, p. 69, doi. 10.1111/bjh.12845
- By:
- Publication type:
- Article
Prognostic impact of monocyte count at presentation in mantle cell lymphoma.
- Published in:
- British Journal of Haematology, 2013, v. 162, n. 4, p. 465, doi. 10.1111/bjh.12409
- By:
- Publication type:
- Article
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 3, p. 380, doi. 10.1007/s10637-022-01326-3
- By:
- Publication type:
- Article
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 2, p. 267, doi. 10.1007/s10637-023-01336-9
- By:
- Publication type:
- Article
Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 6, p. 1263, doi. 10.1007/s10637-022-01281-z
- By:
- Publication type:
- Article
A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 91, doi. 10.1007/s10637-021-01142-1
- By:
- Publication type:
- Article
A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 4, p. 1067, doi. 10.1007/s10637-019-00850-z
- By:
- Publication type:
- Article
Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 869, doi. 10.1007/s10637-018-0570-4
- By:
- Publication type:
- Article
Efficacy and Safety Exposure–Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma.
- Published in:
- AAPS Journal, 2022, v. 24, n. 1, p. 1, doi. 10.1208/s12248-021-00660-3
- By:
- Publication type:
- Article
The Management of Nongastric MALT Lymphomas.
- Published in:
- Oncology (08909091), 2014, v. 28, n. 1, p. 86
- By:
- Publication type:
- Article
MALT Lymphomas: Pathogenesis Can Drive Treatment.
- Published in:
- Oncology (08909091), 2011, v. 25, n. 12, p. 1134
- By:
- Publication type:
- Article
Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 94, n. 3, p. 349, doi. 10.1007/s00280-024-04679-z
- By:
- Publication type:
- Article
Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA).
- Published in:
- Cancers, 2022, v. 14, n. 9, p. N.PAG, doi. 10.3390/cancers14092191
- By:
- Publication type:
- Article
Adverse Event Reporting with Immune Checkpoint Inhibitors in Older Patients: Age Subgroup Disproportionality Analysis in VigiBase.
- Published in:
- Cancers, 2021, v. 13, n. 5, p. 1131, doi. 10.3390/cancers13051131
- By:
- Publication type:
- Article
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax.
- Published in:
- Cancers, 2019, v. 11, n. 6, p. 775, doi. 10.3390/cancers11060775
- By:
- Publication type:
- Article
Do oncologists prefer subspecialty radiology reports? A quality care study.
- Published in:
- Insights into Imaging, 2021, v. 12, n. 1, p. 1, doi. 10.1186/s13244-021-01007-4
- By:
- Publication type:
- Article
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 2, p. 243, doi. 10.1007/s10637-013-9965-4
- By:
- Publication type:
- Article
Thrombotic thrombocytopenic purpura associated with renal failure after autologous transplantation for multiple myeloma successfully treated with rituximab.
- Published in:
- European Journal of Haematology, 2006, v. 77, n. 6, p. 527, doi. 10.1111/j.1600-0609.2006.00758.x
- By:
- Publication type:
- Article
ABCL-022: LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S377, doi. 10.1016/S2152-2650(21)01861-9
- By:
- Publication type:
- Article
Poster: ABCL-022: LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S238, doi. 10.1016/S2152-2650(21)01495-6
- By:
- Publication type:
- Article
Oral Abstract: ABCL-022: LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S203, doi. 10.1016/S2152-2650(21)01278-7
- By:
- Publication type:
- Article
Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S323, doi. 10.1016/j.clml.2017.07.130
- By:
- Publication type:
- Article
The BET Bromodomain Inhibitor (BETi) OTX015 (MK-8628) Upregulates miR-96-5p in Diffuse Large B-Cell Lymphomas (DLBCL).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S105, doi. 10.1016/j.clml.2016.07.151
- By:
- Publication type:
- Article
Correlation between PSA kinetics and PSMA‐PET in prostate cancer restaging: A meta‐analysis.
- Published in:
- European Journal of Clinical Investigation, 2019, v. 49, n. 3, p. N.PAG, doi. 10.1111/eci.13063
- By:
- Publication type:
- Article
Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies.
- Published in:
- 2016
- By:
- Publication type:
- journal article
How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B‐cell lymphoma?
- Published in:
- Hematological Oncology, 2024, v. 42, n. 1, p. 1, doi. 10.1002/hon.3237
- By:
- Publication type:
- Article
New drugs and pharmacological interactions in real life.
- Published in:
- 2021
- By:
- Publication type:
- journal article
A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B‐cell lymphomas.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 1, p. 60, doi. 10.1002/hon.2822
- By:
- Publication type:
- Article
Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Incidence, risk factors and outcome of histological transformation in follicular lymphoma.
- Published in:
- British Journal of Haematology, 2012, v. 157, n. 2, p. 188, doi. 10.1111/j.1365-2141.2012.09054.x
- By:
- Publication type:
- Article
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41).
- Published in:
- Oncologist, 2015, v. 20, n. 10, p. 1149, doi. 10.1634/theoncologist.2015-0180
- By:
- Publication type:
- Article
Genetic alterations in systemic nodal and extranodal non-cutaneous lymphomas derived from mature T cells and natural killer cells.
- Published in:
- Cancer Science, 2012, v. 103, n. 8, p. 1397, doi. 10.1111/j.1349-7006.2012.02321.x
- By:
- Publication type:
- Article
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma.
- Published in:
- EJHaem, 2022, v. 3, n. 3, p. 764, doi. 10.1002/jha2.535
- By:
- Publication type:
- Article